MarketPulse

drug development

62 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

First Turn Management Establishes $35M Stake in Clinical-Stage Biotech Terns

First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.
TERNdrug developmentstock surge
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Perspective Therapeutics to Unveil 2025 Results and Clinical Pipeline Progress

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.
CATXfinancial resultsclinical trials